In a bold leap toward redefining metabolic disease treatment, Hyderabad-based biotech startup Utopia Therapeutics has raised $1.5 million in Seed funding from early-stage investor Whale Tank.
The fresh capital will accelerate the preclinical development of UT009, Utopia’s lead immunotherapeutic candidate designed to combat obesity — a chronic condition affecting over 1 billion people globally. The funding will also push UT009 through key IND-enabling milestones and early human clinical trials.
Founded in 2024 by Uday Saxena and Gopi Kadiyala, Utopia is taking a vaccine-first approach to treat chronic metabolic diseases, starting with obesity. While most solutions rely on drugs or lifestyle interventions, UT009 targets lipid-associated antigens that play a central role in fat accumulation and metabolic imbalance.
“Obesity is a global epidemic with very few lasting solutions. UT009 doesn’t just suppress appetite or block fat — it targets the very root cause of weight gain,” said Saxena and Kadiyala in a joint statement. “With Whale Tank’s backing, we’re moving one step closer to bringing an entirely new class of therapies to the world.”
Utopia’s approach marks a paradigm shift in metabolic medicine, bridging the gap between preventive care and therapeutics through a next-generation vaccine platform.
Beyond UT009, the startup also plans to scale its UT018-based regenerative product line, built on GRAS-qualified, non-pharmaceutical applications, expanding its footprint in metabolic health and wellness.
As the global biotech community watches closely, Utopia Therapeutics is making a powerful case for India’s potential to lead the next wave of immunometabolic innovation.
